학술논문

Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome
Document Type
article
Source
Clinical Infectious Diseases. 75(7)
Subject
Clinical Research
Clinical Trials and Supportive Activities
6.1 Pharmaceuticals
Evaluation of treatments and therapeutic interventions
Good Health and Well Being
COVID-19
Chemokines
CC
Humans
Immunosuppression Therapy
Receptors
CCR5
CCR5
leronlimab
long COVID
immunosuppression
Biological Sciences
Medical and Health Sciences
Microbiology
Language
Abstract
In an exploratory trial treating "long COVID" with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab. Clinical Trials Registration. NCT04678830.